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Abstract
Tuberculosis is an infectious disease, and different treatments have been discovered over the years.
However, patients may develop various drug resistance levels that affect the likelihood of becoming cured or
dying. In this study, we sought to employ data visualization to explore the relationship between treatment
trajectory, as indicated by smear and culture results in the follow-up tests and patient outcomes. A large sample
of patients have been broken down by demographics including age, gender, and drug resistance status. Sankey
diagrams were used to visualize the pathway progression of the patients over time split between two time
periods- months 0-6 and months 6-24. It was determined that the most crucial months of treatment for all drug
resistant types were during months 0-2, since there was high variability within that time frame for all
demographics. It was also observed that younger patients were much more varying test results. It is thus
recommended that the standards be updated to test every month for the first nine months of treatment in order to
better track the pathway variety and that younger patients be more closely monitored throughout the treatment
process. Future studies may investigate the possibility of creating a prediction diagram for patient pathway
progression based on demographic status and past medical information.
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1. Background and Significance
Tuberculosis (TB) is an infection caused by the bacteria called Mycobacterium tuberculosis, which may lay
dormant in the body or be an active infection. It is most commonly located in the lungs, but the bacteria may
also reside within other organs such as the kidney or spine. The bacteria is transmitted through the air
whenever an infected individual coughs, sneezes, etc., and only a few of the germs are needed to be inhaled
in order for another person to become infected. It should be noted, however, that approximately 25% of the
world’s population has latent TB, who are not considered sick or able to transmit the disease.
According to the World Health Organization (WHO), diagnosis and treatment of tuberculosis averts
millions of death, but there is still improvement to be made in regards to patient treatment (WHO 2017).
Since there are varying reasons why some people do not receive treatment, such as lack of healthcare or
knowledge of infection, more efficient and effective diagnosis and treatment is necessary. In addition to an
effective diagnosis and follow-up testing, patients are in need of proper treatment plans. Since people have
varying levels of multidrug resistance (MDR) levels, different drug treatments may not be as effective for
certain patients. In previous studies, the status of “multi-drug resistant” (MDR) tends to be the most
threatening to patients, as those with MDR tend to suffer from higher death rates (Abdelbary 2017). There
also exists a resistant level called “PanS,” which has different resistances than MDR, but is still a significant
threat since there is no treatment regimen. It is thus best to detect drug resistance as soon as possible so that
another drug treatment may be implemented for the patient, as diagrams of untreated TB generally assume a
total duration of only 2 years until self-cure or death (Tiemersma et. al. 2011).
Smear and culture tests are common follow-up tests for TB patients under treatment in order to
monitor the progress of recovery. Smear tests study the signs for TB bacteria while culture tests indicate the
growth of bacteria. Patient status falls into one of four possible categories, depending on whether the smear
reading is positive or negative and whether the culture reading is positive or negative. According to Lab
6

Tests Online, when both smear and culture read positive, there is significant evidence to determine the
presence of the TB micro-bacteria, and the patient is diagnosed as having tuberculosis. If only the smear is
positive, the results are questionable, as the bacteria present may not be that of tuberculosis. If only the
culture is positive, this is a rare occurrence, and usually indicates an error and that further testing is required.
Whenever both smear and culture test as negative, it indicates that no tuberculosis bacteria is present
(Chakravorty et. al. 2005). Using this information, patient prognosis can be tracked over time based on
which of the four statuses possible.
Although those previously conducted projects are beneficial to understanding how to prevent
infection and contamination, this research will help already infected patients by knowing if they are being
properly treated. If not, it can be determined earlier so that more patients may start getting healthier sooner.

1.1 Past-Related Tuberculosis Studies
Currently, most tuberculosis studies have been concerned with factors that impact the infection of
tuberculosis and how to better prevent the infection from developing (Wallis et. al. 2013). For example, the
Tanzania study determined that smoking and HIV positivity are significant risk factors for mortality
(Senkoro et. al. 2010, Mollel and Chilongola 2017, Philips et. al. 2017). These preexisting health concerns
usually indicate that the patients begin treatment at some drug resistant level, making treatment even more
difficult.
It has also been determined that diabetes and multi-drug resistance are risk factors
for cavitary disease, usually a result of prolonged untreated TB (Zhang et. al. 2016 and Raznatovska and
Khudiakov 2018). This indicates that although untreated TB may not directly result in death, it often leads
to further health problems (Chan, Edward D. 2004). Since so many patients may begin treatment with some
form of drug resistance level, the development of TB drug treatments is vital in progression of disease
treatment (Wallis et. al. 2016).
7

The idea of determining optimal treatment combinations is a fairly recent development within the
medical and engineering community. There have already been projects dedicated to determining a drug
combination that results in the highest yield of cured patients with the lowest death yield (Vite 2014 and
Ahuja Shama D. 2011). Recently, many studies are being conducted to visualize complex medical process
for simpler understanding (Lerner 1996, Loorak et. al. 2016, Laptev, Orlov, and Dragunova 2017, and
Alemasoom et. al. 2014).

1.2 Sankey Diagrams
The first draft of a flow diagram based on volume, perhaps the most commonly known diagram resembling
the Sankey diagram principles, was completed in 1869 by Charles Joseph Minard illustrating the size of
Napoleon’s army during the Russian campaign of 1812-1813 (Minard). This graph shows the population of
Napoleon’s army was much larger at the beginning of the campaign, then slowly diminished over time and
distance until Napoleon returned from Russia with considerably depleted forces.
The “Sankey diagram” itself was coined by Captain Matthew Henry Phineas Riall Sankey in 1898 in
order to demonstrate the efficiency of a steam engine by visualizing the volume of energy (in this case,
steam) moving throughout the system and its destinations. This visual allowed easier comprehension of
wasted energy and demonstrating where heat was leaving and entering the engine. Sankey himself intended
the diagram to mainly be used for energy flows within a confined system (Unknown, 1926).
Commercially, the concept of visualizing the data in an engaging way makes communicating ideas
much more attractive for both engineers and clients. Since the eyes naturally are drawn to arrows with a
larger width, this makes drawing attention to the most significant flows much easier, and if the arrow
diminishes over time, then that makes the change between the two appear even more drastic.
This mapping of patient volume over time will be beneficial since it will clearly demonstrate the
volume of patients that are being cured and the number of patients who die due to incomplete or insufficient
8

treatment. Khan et. al. (2015) used the Sankey diagram to better understand the trends of breast cancer
patients, demonstrating its usage in the medical field.
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2. Materials and Methodology
The data was collected for Informational Monitoring and Evaluation System of National Control Program of
Tuberculosis in the Republic of Moldova (SYME TB) over the course of 2009 to 2016. Patients were only
included in the data set if testing proved susceptibility to infection, preventing any unconfirmed tuberculosis
patients from being included. The set of data is composed of the clinical records of 23,160 tuberculosis patients
from diagnosis to the end of treatment. The dataset was cleaned and prepared by Maryam Alimohammadi.
For each patient, attributes were collected, and these attributes have been further divided into either a
variable or a covariate. The covariate is the independent variable impacting the outcome of the dependent
variables. The relevant divisions are as follows:
a. Covariates: Gender (Male or Female), Age (less than 35 years of age, between ages 35 and 55, and
greater than 55 years of age), TB group (MDR, PanS, or Neither)
b. Variables: Smear, Culture, and Culture-Grade
By the end of the 2-year time study, there is an additional response variable designated “Final_Status,”
indicating if the patient’s status classified as “Cured,” “Not Cured,” or “Death.” Based on the NIH
definition (WHO 2010), to obtain the “Cured” status for non-MDR classified patients, there must be at least two
consecutive smear/culture teats with negative readings. However, for MDR patients, there must be at least three
consecutive time periods of negative smear/culture test readings. The “Death” status is designated to any patient
who dies for any reason within the 24 month period. Cases that are neither “Cured” or “Death” cases are
designated as “Not Cured.” The percentages of each demographic was determined (Figure 1).
Variable

Levels

Level Population

Gender

Male

76.715%

Female

23.285%

1

39.468%

Age Group

Description (if necessary)

Less than 35 years of age
10

TB Group

2

44.038%

Between 35 and 55 years of age

3

16.494%

Greater than 55 years of age

MDR

23.246%

Multi-drug Resistance

PanS

65.782%

Susceptible to both Isoniazid and
Rifampicin

Final Status

Neither

10.972%

Cured

82.347%

Death

5.753%

Not Cured

11.9%
Figure 1: Dataset Attribute Analysis

2.1Research Objectives
The main objective of this research project was using data visualization in order to demonstrate patient
treatment progression within certain demographics. By analyzing the typical trends of the treatment pathways of
different demographics, the decision-making process for future TB treatment could be improved. Analyzing
trends may also allow a better understanding of what groups are more at risk when diagnosed with a TB
infection.

2.2 Methodology
The first main task of this project was developing programing code that would count the number of patients
traveling along each possible path according to appropriate measures. Once all the possible paths were properly
accounted for, a new Excel data file was created, only listing the pathways with non-zero values. This data set
was then be loaded into Power BI for visualization. The visualization was completed using the Sankey Diagram
extension on Microsoft’s Power BI, available for free download online. The visual was then rearranged in order
to correspond with the defined layout of the axis.
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2.3 Key Assumptions
Before programming could begin, key assumptions had to be established, as the big data was not perfect and
had to be cleansed for proper diagraming. The key assumptions are as follows:
a. If a patient missed a check-up session, then it is assumed that his or her status remained unchanged
until the next check-up attended
b. This project would only be concerned with the patients who had test readings at time 0. This is to
ensure that only patients present for the full two years are analyzed.
c. Smear would only be classified as “Positive” or “Negative”. Although the dataset had varying
degrees of smear positivity, in order to maintain simplicity in the diagram, culture was the only
reading accounting for varying degrees.
d. Since Smear indicates the presence of the TB bacteria, any culture readings would be considered
false positives, since culture reads the severity of the infection. Therefore, Negative Smear only has
a 0 Culture grade, but Positive Smear has varying grades of Culture.
e. If a patient were to leave the system before the time study deadline of 24 months with the status
“Not Cured,” they would be counted as in the “Death” category. This is due to the fact that if the
patient weren’t cured yet, it is assumed that they would continue treatment before the 24 month time
period was up. The only time “Death” and “Not Cured” are differentiated is in the final month.

2.4 Program Diagraming
The programming was completed using formulas already installed in Excel. In order for this visualization to
form properly, the data was arranged in a format mapping out the quantities from origins to targets. This
determined that in addition to the programming separating the data according to different demographics, it had
to be recorded in a specific way in order to create a Sankey diagram in accordance with the extension
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requirements. The following format required for the Sankey diagram is similar to the example below (Figure
2).
Origin

Target

Quantity

A

B

10

A

C

2

B

D

7

Figure 2: Sankey Diagram Sample

2.5 Sankey Diagram Design
For each diagram, the y-axis is a reading of the patient’s status, with the positive direction indicating
improvement and the negative direction signifying health decline. Since each test reading contains a smear and
culture reading, the axis is sorted first by smear reading, with negative readings lying on the positive direction
of the y-axis, then by culture, with lower positive readings lying in the positive y-axis direction. The xaxis demonstrates the progression over time in units of months.
In order to keep the diagrams relatively simple, the diagrams are broken up into 2 distinct time periods:
Month 1-6 and Month 6-24. Since the first 6 months are the most crucial in the treatment process, it was
deemed important that those months be separated from the later months of testing. Each age group can be seen
off to the side (A for age group 1, B for age group 2, C for age group 3), and the number of patients included in
the first time period of the figure.
In addition to separating the charts into different time periods, they are also divided according to various
patient demographics. First, the pathways were constructed when only separated by two categories- gender and
drug status. Drug status is the most crucial demographic to study, as this is the most impactful attribute directing
patient treatment progression. In addition to drug resistance level, the patients were also separated based on
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gender, since this was more insightful than separation based on age groups. Once the Gender/TB Group graphs
were completed, they were further broken down based on age groups within each demographic.
It was deemed vital that the diagrams were overall organized with a clear direction for decline and
improvement. Since the diagrams are automatically generated by the program, any visual complication is not
intentional.
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3. Diagram Results
In this section, each general diagram will be analyzed before being broken down according to age groups. This
general analysis of a broader group further broken down with the more specific graphs allowed further insight
into an initial broad analysis. Within each section, the different month sets can be seen, each further broken
down by age group.

3.1 Male MDR
For the first 6 months within this demographic, most patients don’t change test results between intervals
(Figure 3). In month 1, the only patients who died were previously tested with readings of negative smear
results. However, later in month 5, the only patients designated with “Death” had previously had positive smear
and culture readings, but this is to be expected. Throughout the 6 month period, there are multiple cases of
patients with positive TB readings being designated as “Cured” in the next time period. The majority of cured
patients previously tested having no signs of smear, but from the patients who had previously shown signs of
smear, there was an even distribution getting cured.
During the remaining months, the patients were much more stagnant in test readings, with relatively few
patients classified as “Cured” or “Dead” in each time period. In the last time period, however, there were no
deaths occurring, only instances of patients becoming designated as “Cured” or continuing treatment (Figure
4).
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3.1.1. Month 0-6

a:
145

b:
165

c:
52

C:
Figure 3: Sankey Diagram for Male MDR Patients Months 0-6
16

3.1.2. Month 6-24

a:
66

b:
59

c:
14

C:
Figure 4: Sankey Diagram for Male MDR Patients Months 6-24
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3.2 Female MDR
During the first 6 months, the only occurring deaths were in age groups 1 and 2 (Figures 5a and 5b), so this
may signify that younger patients are more at risk for death during this first time period. However, the most
patients recorded as being cured were also in the first two age groups, so this could also signify that the younger
ages work in more extremes. That is to say, younger patients don’t tend to stay stagnant in treatment status and
are quicker to reaching either a “Cured” or “Death” status within the first six months of treatment.
For the remaining 18 months, there were few instances of degrading in test results before dying. Instead,
most patients stayed within the past test reading, only moving when exiting the system. Again, there were no
deaths recorded in the final time period, but there appeared to be significant portions of patients dying in other
months, with the most deaths occurring in either age group 1 or 2 (Figures 6a and 6b).
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3.2.1. Month 0-6

a:
62

b:
27

c:
13

C:
Figure 5: Sankey Diagram of Female MDR Patients Months 0-6
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3.2.2. Month 6-24

a:
21

b:
10

c:
6

C:
Figure 6: Sankey Diagram of Female MDR Patients Months 6-24
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3.3 Male PanS
Within the first 6 months, the largest proportion of patients within this time period were diagnosed as having no
evidence of the TB bacteria, implying that these patients were simply waiting in order to be officially
designated as “Cured,” and in fact these patients were usually the only ones designated into the “Cured” status.
However, in younger ages, there were other patients from different test categories (Figure 7a and 7b). It should
also be noted that the first two age groups are the only ones suffering from patients dying during the course of
treatment, and the third age group had no deaths, but also very little “Cured” patients.
From months 6-24, there were very few patients with positive readings for the TB infection, and many
of these patients were eventually classified as “cured.” Month 9 contained the largest proportion of patients
becoming cured, but that was also the month with the highest records of patients dying, though it was much
smaller than the amount cured (Figure 8). Patients in the second age group tended to leave the system faster
than the other age groups, with the oldest patients remaining in the treatment system longer (Figure 8b).

21

3.3.1. Month 0-6

a:
486

b:
623

c:
359

C:
Figure 7: Sankey Diagram of Male PanS Patients Months 0-6
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3.3.2. Month 6-24

a:
453

b:
585

c:
320

C:
Figure 8: Sankey Diagram of Male PanS Patients Months 6-24
23

3.4 Female PanS
Within the first six months, the second age group recorded the highest rates of cured patients and there were
only occurrences of death at month 5, but there was a more even spread of different test results, especially
compared to age groups 1 and 3, which have the majority of patients testing of negative smear and culture
results (Figure 9a and 9c). Age group 3 also only had death at month 5, but there were sparse instances of
patients becoming classified as cured (Figure 9c).
During the remaining months in the treatment process, very few patients remained in the treatment
process until month 24. Most patients were cured at month 9, and patients who died were evenly spread
between months 9 and 12, with some occurring at month 18 (Figure 10). It should be noted that most deaths
were patients who had not previously shown signs of the TB infection. Again, the majority of the patients
within this demographic were showing no signs of infection, with very few having a positive smear reading.
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3.4.1. Month 0-6

a:
284

b:
185

c:
99

C:
Figure 9: Sankey Diagram of Female PanS Patients Months 0-6
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3.4.2. Month 6-24

a:
271

b:
171

c:
92

C:
Figure 10: Sankey Diagram of Female PanS Patients Months 6-24
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3.5 Male Neither
From the start of the time study to month 6, the highest rates of patients becoming classified as “Cured” or
“Death” occurred up to month 3. After month 3, there were much less significant instances of patients ether
dying or being cured, instead staying stagnant in the current test readings (Figure 11). This is better than the
patients’ health readings declining, but there is concern that many patients aren’t improving despite treatment.
For the remainder of the time study, there were large portions of patients being cured at months 9 and
18, but the highest records of death were also at month 9. No patients died at month 24, and in fact a relatively
small amount needed to continue treatment. The youngest age group experienced the highest rates of death, with
patients dying at months 9, 12, and 18 (Figure 12a). All age groups showed not much test reading variety,
instead keeping consistent test readings for each time period (Figure 12).

27

3.5.1. Month 0-6

a:
80

b:
97

c:
29

C:
Figure 11: Sankey Diagram of Male Neither Patients Months 0-6
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3.5.2. Month 6-24

a:
47

b:
53

c:
19

C:
Figure 12: Sankey Diagram of Male Neither Patients Months 6-24
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3.6 Female Neither
For the first six months, the majority of patients within this demographic have tested negative for traces of
smear, and those who show positive signs either quickly exit the process or improve readings by testing
negative for smear. Age group 1 is the only group with a maintained different test type for all six months
(Figure 13a).
During the remaining 18 months, the only age group with a test reading other than negative smear is the
first age group (Figure 14a). Death only occurred at months 9 and 12, but the majority of the patients within
this demographic were ultimately cured, with a smaller portion continuing treatment. Since most patients had a
negative smear reading, most were waiting for the “Cured” status to become official, they didn’t degrade in test
readings.
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3.6.1. Month 0-6

a:
31

b:
17

c:
18

C:

Figure 13: Sankey Diagram of Female Neither Patients Months 0-6
31

3.6.2. Month 6-24

a:
24

b:
13

c:
9

C:
Figure 14: Sankey Diagram of Female Neither Patients Months 6-24
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4. Discussion and Analysis
In this section, the trends and comparisons between different demographics were completed. Within all six
demographics, there were instances of patients testing positive for smear and/or culture, but then being
considered cured in the next time period. Since it was required that patients test negative for smear/culture for at
least two consecutive time periods in order to be considered “Cured,” this could be the result of a recording
error or patients being clear for 2 months before the final month.

4.1 Gender (Male vs. Female)
When comparing the males and females in this study, it should be noted that there were many more male
patients than female, so the male patients may offer a more complex and detailed picture than the female
demographic. The male population experiences higher levels of death and cured patients, but since the male
population is larger than the female, this outcome is understandable. Overall, there didn’t appear to be a
significant difference between the gender demographics within this study.

4.2 Month Range (0-6 Months vs. 6-24 Months)
Since patient readings are described every month for the first six months, there is more variety in test results
than in the months following, where the patient is only tested every 3-6 months. Since the first few months of
treatment are the most crucial, the variety in most test results is understandable, as different treatments are
tested in order to determine if they are effective.
In the later months, month 9 has shown to be a major month, with many records of patients becoming
cured or dying. After month 9, most test readings remain stagnant, with some proportions leaving the system.

4.3 Drug Resistance Type (MDR vs. PanS vs. Neither)
The MDR patients experienced the highest proportions of death rates among the three different drug resistant
levels. These patients also experienced the most complexity in changing test grades. There were much more
33

variation in the amount of routes different patient test readings would take, making trend identification more
difficult.
The patients diagnosed with PanS resistance status tended to have much lower rates of positive smear
and culture readings. That is, the majority of patients would test with no readings for the TB bacteria. This is
odd, however, because there are very few reports of cured patients in the first six months, even though the
patients tended to stay consistent in testing negative. Once the time study reached month 9, however, there were
much greater proportions of patients becoming designated as “Cured.” This aligns with the WHO’s
consideration that PanS patients should be cured by month 9, however, there was a decent number still within
the treatment process. There were also few reports of patients dying, so it is unclear why it took so long for
patients to be designated “Cured.”
The patients neither MDR nor PanS experienced the highest rates of deaths and cured patients during the
first 3 months of treatment, but then most patients remained stationary in status readings. There weren’t any
particularly large ratings of cured patients until month 9, coinciding with the WHO’s predications of being
cured within 9 months.

4.4 Age (1 vs. 2 vs. 3)
The youngest age group (1) was the most responsive over the course of this study. That is, younger patients
tended “exit the system” faster (i.e. were cured or died), and over the course of time, these patients had more
various test readings before eventually exiting the system. Older patients (age group 3) tended to stay within the
system longer with the same test results. Age group 2 results was much more dependent on drug resistant status.
For instance, MDR patients had much more variety in test results than PanS patients, who in turn had more
variety than patients without a drug resistance.
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4.5 Overall Analysis
One of the main takeaways concerns the rate at which the patient reports back for a check-up. The standard is 2
months, but after observing the importance of the first six months, as well as how important Month 9 is, it could
be beneficial to schedule monthly appointments for the first 9 months of treatment instead of the first 6. This
could allow further insight into when the patients stop drastically exiting the system and settle into a stagnant
test result for an unexpected duration of time. However, a great emphasis should be placed on the time period
containing the first two months, since these months contained the most variability.
In addition to possible revision to the standard checkup rate, age should also be investigated. Since the
younger patients are much more reactive during treatment, these patients should be more closely monitored in
the future.
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6. Conclusion and Future Works
Tuberculosis is a disease that affects different portions of the world, be it active or latent. In order to better
understand the trends of patient treatment progress, diagrams were created to display the quantities of patients
over time according to test results. Using these diagrams, trends were identified overall and according to
different demographics.
The main shortcoming of this research is that only quantities of patients were tracked throughout the
treatment process. Although this allowed general trends to be identified from the different diagrams, this did not
track individual patient progression.
In future studies, it would be beneficial to design a new visualization diagraming program in order to
track typical patient progression over time according to each demographic whilst including the variation along
the path. The inclusion of history along the entire treatment path can allow for future patients to compare his or
her own progression path to a standard for treatment.
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